This Research Article by Dr.
Spinal cord injury (SCI) causes long-lasting damage in the spinal cord that leads to paraparesis, paraplegia, quadriplegia and other lifetime disabilities. The emergence of antibody treatment has paved a new pathway for the management of SCI. In this current review, Professor Weijiang Zhao and Doctor Danyang Tang summarize the experimentally therapeutic application of antibodies in SCI.
Spinal cord injury (SCI) causes long-lasting damage in the spinal cord that leads to paraparesis, paraplegia, quadriplegia and other lifetime disabilities. The underlying mechanisms responsible for the failure of axonal regeneration after SCI remain only partially understood. Although a spectrum of medical treatments has been made available for this disease, the therapeutic effects remain disappointing. The emergence of antibody treatment has paved a new pathway for the management of SCI. In this current review, the authors summarize the application of antibodies in SCI in studies of myelin repair, neuroprotection, axon outgrowth, and anti-immune reaction.
For myelin repair, the therapeutic functions and underlying mechanisms for antibodies targeting inhibitory molecules such as Nogo-A, myelin-associated glycoprotein (MAG), Nogo-66 receptor (NgR), leucine rich repeat and Ig domain containing Nogo receptor interacting protein-1 (LINGO-1),
Despite the significant limitations of antibody treatment, the authors are still confident about the future application of antibodies as a promising therapeutic means to counteract the damage caused by SCI.
For more information about the article please visit http://benthamscience.com/journals/cns-and-neurological-disorders-drug-targets/article/145554/